Prothena Corp Public Ltd Co (PRTA) stock
PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3017% below fair value
$8.16−0.07 (-0.85%)
Close on Nov 13, 2026Market cap $418.91MP/E –Yield –
Prothena Corp Public ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Prothena Corp Public's ebitda for the twelve months ending Sep 30, 2026 was -$33.28M. For fiscal 2025 it was -$213.75M. The highest annual figure on record is $73.09M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$213.75M | – |
| FY2024 | Dec 31, 2024 | -$153.67M | – |
| FY2023 | Dec 31, 2023 | -$190.11M | – |
| FY2022 | Dec 31, 2022 | -$130.81M | -279.0% |
| FY2021 | Dec 31, 2021 | $73.09M | – |
| FY2020 | Dec 31, 2020 | -$111.22M | – |
| FY2019 | Dec 31, 2019 | -$84.13M | – |
| FY2018 | Dec 31, 2018 | -$155.64M | – |
| FY2017 | Dec 31, 2017 | -$152.19M | – |
| FY2016 | Dec 31, 2016 | -$157.11M | – |
| FY2015 | Dec 31, 2015 | -$79.13M | – |
| FY2014 | Dec 31, 2014 | -$5.91M | – |
| FY2013 | Dec 31, 2013 | -$39.77M | – |
| FY2012 | Dec 31, 2012 | -$40.94M | – |
| FY2011 | Dec 31, 2011 | -$28.85M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$18.61M | – |
| Q2 FY2026 | Jun 30, 2026 | -$20.90M | – |
| Q1 FY2026 | Mar 31, 2026 | $30.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.99M | – |
| Q3 FY2025 | Sep 30, 2025 | -$40.01M | – |
| Q2 FY2025 | Jun 30, 2025 | -$84.39M | -244.0% |
| Q1 FY2025 | Mar 31, 2025 | -$65.36M | – |
| Q4 FY2024 | Dec 31, 2024 | -$64.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$66.29M | -729.1% |
| Q2 FY2024 | Jun 30, 2024 | $58.61M | – |
| Q1 FY2024 | Mar 31, 2024 | -$81.31M | – |
| Q4 FY2023 | Dec 31, 2023 | -$78.24M | -63196.0% |
| Q3 FY2023 | Sep 30, 2023 | $10.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$66.28M | – |
| Q1 FY2023 | Mar 31, 2023 | -$56.12M | – |
| Q4 FY2022 | Dec 31, 2022 | $124.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$50.15M | -145.8% |
| Q2 FY2022 | Jun 30, 2022 | -$43.03M | -252.4% |
| Q1 FY2022 | Mar 31, 2022 | -$37.76M | – |
| Q4 FY2021 | Dec 31, 2021 | -$32.85M | – |
| Q3 FY2021 | Sep 30, 2021 | $109.51M | – |
| Q2 FY2021 | Jun 30, 2021 | $28.24M | – |
| Q1 FY2021 | Mar 31, 2021 | -$31.81M | – |
| Q4 FY2020 | Dec 31, 2020 | -$29.95M | – |
| Q3 FY2020 | Sep 30, 2020 | -$30.46M | – |
| Q2 FY2020 | Jun 30, 2020 | -$26.35M | – |
| Q1 FY2020 | Mar 31, 2020 | -$24.46M | – |
| Q4 FY2019 | Dec 31, 2019 | -$22.87M | – |
| Q3 FY2019 | Sep 30, 2019 | -$20.58M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.11M | – |
| Q1 FY2019 | Mar 31, 2019 | -$22.57M | – |
| Q4 FY2018 | Dec 31, 2018 | -$21.93M | – |
| Q3 FY2018 | Sep 30, 2018 | -$23.53M | – |
| Q2 FY2018 | Jun 30, 2018 | -$62.27M | – |
| Q1 FY2018 | Mar 31, 2018 | -$47.91M | – |
| Q4 FY2017 | Dec 31, 2017 | -$46.54M | – |
| Q3 FY2017 | Sep 30, 2017 | -$52.77M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.37M | – |
| Q1 FY2017 | Mar 31, 2017 | -$35.51M | – |
| Q4 FY2016 | Dec 31, 2016 | -$48.36M | – |
See a number that looks wrong?